PamGene Platform Adopted for Kinase Drug R&D Program
Collaboration with Johnson & Johnson Pharmaceutical Research & Development
The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.